Raloxifene dimethyl-β-CD cochleate formulations were found to be successful in reducing breast tumors. Further matrix metalloproteinase-2 (MMP-2) enzyme was also found to be inhibited. The gene discussed is MMP2; the disease is breast neoplasm.